Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality

Taichi Sugizaki, Shunshun Zhu, Ge Guo, Akiko Matsumoto, Jiabin Zhao, Motoyoshi Endo, Haruki Horiguchi, Jun Morinaga, Zhe Tian, Tsuyoshi Kadomatsu, Keishi Miyata, Hiroshi Itoh, Yuichi Oike

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A favorable effect of an inhibitor of the sodium–glucose cotransporter 2 (SGLT2i) on mortality of diabetic patients was recently reported, although mechanisms underlying that effect remained unclear. Here, we examine SGLT2i effects on survival of diabetic mice and assess factors underlying these outcomes. To examine SGLT2i treatment effects in a model of severe diabetes, we fed genetically diabetic db/db mice a high-fat diet and then assessed outcomes including diabetic complications between SGLT2i TA-1887-treated and control mice. We also compare effects of SGLT2i TA-1887 with those of lowering blood glucose levels via insulin treatment. Untreated db/db mice showed remarkable weight loss, or cachexia, while TA-1887-treated mice did not but rather continued to gain weight at later time points and decreased mortality. TA-1887 treatment prevented pancreatic beta cell death, enhanced preservation of beta cell mass and endogenous insulin secretion, and increased insulin sensitivity. Moreover, TA-1887 treatment attenuated inflammation, oxidative stress, and cellular senescence, especially in visceral white adipose tissue, and antagonized endothelial dysfunction. Insulin treatment of db/db mice also prevented weight loss and antagonized inflammation and oxidative stress. However, insulin treatment had less potent effects on survival and prevention of cellular senescence and endothelial dysfunction than did TA-1887 treatment. SGLT2i treatment prevents diabetic cachexia and death by preserving function of beta cells and insulin target organs and attenuating complications. SGLT2i treatment may be a promising therapeutic strategy for type 2 diabetes patients with morbid obesity and severe insulin resistance.

Original languageEnglish
Article number12
Journalnpj Aging and Mechanisms of Disease
Volume3
Issue number1
DOIs
Publication statusPublished - 2017 Dec 1

Fingerprint

Cachexia
Mortality
Insulin
Therapeutics
Cell Aging
Insulin Resistance
Weight Loss
Oxidative Stress
Inflammation
White Adipose Tissue
Morbid Obesity
Intra-Abdominal Fat
Insulin-Secreting Cells
High Fat Diet
Diabetes Complications
Type 2 Diabetes Mellitus
Weight Gain
Blood Glucose
Cell Death

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Ageing

Cite this

Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality. / Sugizaki, Taichi; Zhu, Shunshun; Guo, Ge; Matsumoto, Akiko; Zhao, Jiabin; Endo, Motoyoshi; Horiguchi, Haruki; Morinaga, Jun; Tian, Zhe; Kadomatsu, Tsuyoshi; Miyata, Keishi; Itoh, Hiroshi; Oike, Yuichi.

In: npj Aging and Mechanisms of Disease, Vol. 3, No. 1, 12, 01.12.2017.

Research output: Contribution to journalArticle

Sugizaki, T, Zhu, S, Guo, G, Matsumoto, A, Zhao, J, Endo, M, Horiguchi, H, Morinaga, J, Tian, Z, Kadomatsu, T, Miyata, K, Itoh, H & Oike, Y 2017, 'Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality', npj Aging and Mechanisms of Disease, vol. 3, no. 1, 12. https://doi.org/10.1038/s41514-017-0012-0
Sugizaki, Taichi ; Zhu, Shunshun ; Guo, Ge ; Matsumoto, Akiko ; Zhao, Jiabin ; Endo, Motoyoshi ; Horiguchi, Haruki ; Morinaga, Jun ; Tian, Zhe ; Kadomatsu, Tsuyoshi ; Miyata, Keishi ; Itoh, Hiroshi ; Oike, Yuichi. / Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality. In: npj Aging and Mechanisms of Disease. 2017 ; Vol. 3, No. 1.
@article{1455f3939b094b1ab374c8be1ba75cf9,
title = "Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality",
abstract = "A favorable effect of an inhibitor of the sodium–glucose cotransporter 2 (SGLT2i) on mortality of diabetic patients was recently reported, although mechanisms underlying that effect remained unclear. Here, we examine SGLT2i effects on survival of diabetic mice and assess factors underlying these outcomes. To examine SGLT2i treatment effects in a model of severe diabetes, we fed genetically diabetic db/db mice a high-fat diet and then assessed outcomes including diabetic complications between SGLT2i TA-1887-treated and control mice. We also compare effects of SGLT2i TA-1887 with those of lowering blood glucose levels via insulin treatment. Untreated db/db mice showed remarkable weight loss, or cachexia, while TA-1887-treated mice did not but rather continued to gain weight at later time points and decreased mortality. TA-1887 treatment prevented pancreatic beta cell death, enhanced preservation of beta cell mass and endogenous insulin secretion, and increased insulin sensitivity. Moreover, TA-1887 treatment attenuated inflammation, oxidative stress, and cellular senescence, especially in visceral white adipose tissue, and antagonized endothelial dysfunction. Insulin treatment of db/db mice also prevented weight loss and antagonized inflammation and oxidative stress. However, insulin treatment had less potent effects on survival and prevention of cellular senescence and endothelial dysfunction than did TA-1887 treatment. SGLT2i treatment prevents diabetic cachexia and death by preserving function of beta cells and insulin target organs and attenuating complications. SGLT2i treatment may be a promising therapeutic strategy for type 2 diabetes patients with morbid obesity and severe insulin resistance.",
author = "Taichi Sugizaki and Shunshun Zhu and Ge Guo and Akiko Matsumoto and Jiabin Zhao and Motoyoshi Endo and Haruki Horiguchi and Jun Morinaga and Zhe Tian and Tsuyoshi Kadomatsu and Keishi Miyata and Hiroshi Itoh and Yuichi Oike",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41514-017-0012-0",
language = "English",
volume = "3",
journal = "npj Aging and Mechanisms of Disease",
issn = "2056-3973",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality

AU - Sugizaki, Taichi

AU - Zhu, Shunshun

AU - Guo, Ge

AU - Matsumoto, Akiko

AU - Zhao, Jiabin

AU - Endo, Motoyoshi

AU - Horiguchi, Haruki

AU - Morinaga, Jun

AU - Tian, Zhe

AU - Kadomatsu, Tsuyoshi

AU - Miyata, Keishi

AU - Itoh, Hiroshi

AU - Oike, Yuichi

PY - 2017/12/1

Y1 - 2017/12/1

N2 - A favorable effect of an inhibitor of the sodium–glucose cotransporter 2 (SGLT2i) on mortality of diabetic patients was recently reported, although mechanisms underlying that effect remained unclear. Here, we examine SGLT2i effects on survival of diabetic mice and assess factors underlying these outcomes. To examine SGLT2i treatment effects in a model of severe diabetes, we fed genetically diabetic db/db mice a high-fat diet and then assessed outcomes including diabetic complications between SGLT2i TA-1887-treated and control mice. We also compare effects of SGLT2i TA-1887 with those of lowering blood glucose levels via insulin treatment. Untreated db/db mice showed remarkable weight loss, or cachexia, while TA-1887-treated mice did not but rather continued to gain weight at later time points and decreased mortality. TA-1887 treatment prevented pancreatic beta cell death, enhanced preservation of beta cell mass and endogenous insulin secretion, and increased insulin sensitivity. Moreover, TA-1887 treatment attenuated inflammation, oxidative stress, and cellular senescence, especially in visceral white adipose tissue, and antagonized endothelial dysfunction. Insulin treatment of db/db mice also prevented weight loss and antagonized inflammation and oxidative stress. However, insulin treatment had less potent effects on survival and prevention of cellular senescence and endothelial dysfunction than did TA-1887 treatment. SGLT2i treatment prevents diabetic cachexia and death by preserving function of beta cells and insulin target organs and attenuating complications. SGLT2i treatment may be a promising therapeutic strategy for type 2 diabetes patients with morbid obesity and severe insulin resistance.

AB - A favorable effect of an inhibitor of the sodium–glucose cotransporter 2 (SGLT2i) on mortality of diabetic patients was recently reported, although mechanisms underlying that effect remained unclear. Here, we examine SGLT2i effects on survival of diabetic mice and assess factors underlying these outcomes. To examine SGLT2i treatment effects in a model of severe diabetes, we fed genetically diabetic db/db mice a high-fat diet and then assessed outcomes including diabetic complications between SGLT2i TA-1887-treated and control mice. We also compare effects of SGLT2i TA-1887 with those of lowering blood glucose levels via insulin treatment. Untreated db/db mice showed remarkable weight loss, or cachexia, while TA-1887-treated mice did not but rather continued to gain weight at later time points and decreased mortality. TA-1887 treatment prevented pancreatic beta cell death, enhanced preservation of beta cell mass and endogenous insulin secretion, and increased insulin sensitivity. Moreover, TA-1887 treatment attenuated inflammation, oxidative stress, and cellular senescence, especially in visceral white adipose tissue, and antagonized endothelial dysfunction. Insulin treatment of db/db mice also prevented weight loss and antagonized inflammation and oxidative stress. However, insulin treatment had less potent effects on survival and prevention of cellular senescence and endothelial dysfunction than did TA-1887 treatment. SGLT2i treatment prevents diabetic cachexia and death by preserving function of beta cells and insulin target organs and attenuating complications. SGLT2i treatment may be a promising therapeutic strategy for type 2 diabetes patients with morbid obesity and severe insulin resistance.

UR - http://www.scopus.com/inward/record.url?scp=85041815856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041815856&partnerID=8YFLogxK

U2 - 10.1038/s41514-017-0012-0

DO - 10.1038/s41514-017-0012-0

M3 - Article

VL - 3

JO - npj Aging and Mechanisms of Disease

JF - npj Aging and Mechanisms of Disease

SN - 2056-3973

IS - 1

M1 - 12

ER -